75A50122C00061↗
Mapp Biopharmaceutical, Inc. received this contract from Barda - Aspr / Daappo / Barda Dcma, Office of Assistant Secretary for Preparedness and Response: $111.14M obligated so far for drugs and biologicals. It runs to 2030-09-30, or to 2032-09-29 if every option is exercised.
Key facts · data as of Oct 22, 2026
- Recipient
- Mapp Biopharmaceutical, Inc.
- Awarding agency
- Office of Assistant Secretary for Preparedness and Response (Department of Health and Human Services)
- Contracting office
- Barda - Aspr / Daappo / Barda Dcma (75A501)
- Obligated to date
- $111.14M
- Potential value
- $942.78M
- Ends
- 2030-09-30
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 22, 2026.
Cite this page: SpendQuery, Award 75A50122C00061, data as of Oct 22, 2026, https://spendquery.com/award?id=CONT_AWD_75A50122C00061_7505_-NONE-_-NONE-
Mapp Biopharmaceutical, Inc.: all federal awards · Department of Health and Human Services: spending · Barda - Aspr / Daappo / Barda Dcma: what it buys
PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES
What it is
- Product or service
- Drugs and Biologicals (PSC 6505)
- Industry
- Research and Development in Biotechnology (Except Nanobiotechnology) (NAICS 541714)
- Contracting office
- Barda - Aspr / Daappo / Barda Dcma (75A501)
- Competition
- Full and open competition · 2 offers received
- Pricing
- Cost plus fixed fee
- How it was bought
- Standalone contract
- Solicitation
- 75A50121R00038
- Where the work is
- San Diego, CA · district CA-51
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
23 actions since 2022-10-12. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-09-18 | P00023 | Funding only | $322.1K | THE PURPOSE OF THIS MODIFICATION IS TO: 1) PROVIDE SUPPLEMENTAL FUNDING FOR CLIN 00013 IN THE AMOUNT OF $322,131 2) REVISE THE 061 STATEMENT OF WORK |
| 2026-07-27 | P00022 | Funding only | $32.58M | THE PURPOSE OF THIS MODIFICATION IS TO: 1. FUND CLIN 0003A IN THE AMOUNT OF $32,580,161.00 2. UPDATE STATE OF WORK TO SUPPORT THE BUNDIBUGYO OUTBREAK RESPONSE 3. THE CONTRACT IS HEREBY DESIGNATED AS A DPAS RATED ORDER: DO-M3. ISSUE PRIORITY RATI |
| 2026-07-08 | P00021 | Supplemental agreement (work within scope) | $3.23M | THE PURPOSE OF THIS MODIFICATION IS TO: 1) TRANSFER OF MATERIAL FROM BARDA CONTRACT NO. 75A50122C00061 (061) TO BARDA CONTRACT NO. HHSO100201600021C (21C). 2) FUND CLIN 0001 IN THE AMOUNT OF $2,841,678.00 AND FUND CLIN 0003A IN THE AMOUNT OF $385, |
| 2026-05-28 | P00020 | Administrative change | $0 | THE PURPOSE OF THIS NO COST MODIFICATION IS TO UPDATE ARTICLE C.1 STATEMENT OF WORK. |
| 2026-05-12 | P00019 | Administrative change | $0 | THE PURPOSE OF THIS NO COST MODIFICATION TO (1) DRUG SUBSTANCE (DS) AND DRUG PRODUCT (DP) MATERIAL TO BE REMOVED FROM CLINICAL SUPPLY TO QUARANTINE STATUS, (2) TRANSFER GOVERNMENT FURNISHED PROPERTY TO MAPP FOR FURTHER IN-HOUSE DEVELOPMENT, (3) UPDAT |
| 2026-03-12 | P00018 | Supplemental agreement (work within scope) | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - TRANSFER GFP TO MAPP CONTACT 21C, EXTEND POP FOR CLIN 0001 & 0006 |
| 2025-07-11 | P00017 | Supplemental agreement (work within scope) | $49.95M | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - TRANSFER GFP |
| 2025-04-18 | P00016 | Administrative change | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - TRANSFER GFP |
| 2025-04-01 | P00015 | Administrative change | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - TRANSFER GFP |
| 2025-03-10 | P00014 | Supplemental agreement (work within scope) | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - INCORPORATE NEW SOW, UPDATE QUALITY AGREEMENT |
| 2025-01-13 | P00013 | Supplemental agreement (work within scope) | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - INCORPORATE NEW SOW |
| 2024-12-05 | P00012 | Administrative change | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - INCORPORATE RATE LETTER MOD |
| 2024-08-07 | P00011 | Administrative change | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - INCORPORATE RATE LETTER MOD |
| 2024-06-03 | P00010 | Administrative change | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - TRANSFER PROPERTY MOD |
| 2024-05-28 | P00009 | Administrative change | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - TRANSFER PROPERTY MOD |
| 2024-05-15 | P00008 | Supplemental agreement (work within scope) | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES |
| 2024-05-09 | P00007 | Administrative change | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES |
| 2023-12-14 | P00006 | Administrative change | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES |
| 2023-09-22 | P00005 | Option exercised | $8.56M | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES |
| 2023-03-07 | P00004 | Administrative change | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES |
| 2023-02-19 | P00003 | Administrative change | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES |
| 2022-12-22 | P00002 | Additional work (new agreement) | $16.51M | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES |
| 2022-10-12 | P00001 | Change order | $0 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-22). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗